Viridian Therapeutics (VRDN) investor relations material

Introduction and purpose

• FDA approved Lumvoa (veligrotug/veligrotug-vvze) as the first treatment for thyroid eye disease (TED) with data for both active and chronic forms, marking the company's first FDA-approved product.

• TED is a rare autoimmune disease causing inflammation and vision impairment.

• Lumvoa is positioned as a differentiated therapy addressing significant unmet needs in TED.

Details of approval or decision

• Lumvoa received FDA approval under Priority Review, supported by two pivotal phase 3 trials (THRIVE and THRIVE-2), and is indicated for TED regardless of disease activity or duration.

• It is the first TED therapy with a label including both active and chronic patient data.

• Approved for a streamlined 12-week course of therapy, completed in five infusions of 10 mg/kg IV every three weeks.

• Physicians can prescribe Lumvoa immediately following approval.

Impact on industry and stakeholders

• Launch targets a $2 billion annual TED market with low current penetration and significant unmet need.

• Focused commercial strategy targets 2,000 core prescribers responsible for over 80% of IGF-1R scripts.

• Rapid uptake anticipated due to favorable market dynamics, mature referral pathways, and Lumvoa’s convenience.

• Comprehensive patient support program (ViridianCares) established to ensure access and assistance.